MARCO ISLAND, Fla.--(BUSINESS WIRE)-- <\/p>\n
(AGBT) \u2013 Agilent Technologies Inc. (NYSE:A) today expanded its target-enrichment platform with the SureSelect XT Human Methyl-Seq system for epigenetic research into DNA methylation sites. It is the first comprehensive DNA methylation discovery system using target enrichment. Agilent will unveil the product at the Advances in Genome Biology and Technology meeting here tomorrow. <\/p>\n
Agilent SureSelect XT Methyl-Seq is a unique in-solution tool for analyzing under- and over-methylated cytosine sites on the human genome. The assay combines SureSelect, the leading target-enrichment platform, with bisulfite sequencing, the gold standard for DNA methylation research and the first comprehensive discovery system. This enables unprecedented sequence coverage of only the most relevant regions for epigenetic studies, including those associated with a wide range of disorders such as cancer, imprinting disorders, behavioral and mental disorders, and many others. <\/p>\n
\u201cDNA methylation is a key epigenetic feature,\u201d said John Stamatoyannopoulos, director of the Northwest Reference Epigenome Mapping Center at the University of Washington. \u201cThe availability of a cost-effective platform that intelligently targets millions of CpGs for bisulfite sequencing will greatly reduce the cost and expand the scope and utility of genome-scale DNA methylation analysis.\u201d <\/p>\n
\u201cThe kit covers all interesting methyl-cytosine sites for cancer research in the genome at an excellent effort-to-output ratio,\u201d said Michal-Ruth Schweider, MD, Ph.D., Max Planck Institute for Molecular Genetics. <\/p>\n
\u201cWe\u2019re very pleased to offer this new tool to meet growing interest from the medical research community,\u201d said Robert Schueren, Agilent vice president and general manager, Genomics. \u201cBecause abnormal methylation is reversible, this type of analysis holds great promise for the discovery of therapies.\u201d <\/p>\n
Agilent SureSelect XT Methyl-Seq allows researchers to analyze over 3.7 million individual CpG dinucleotide sequences for their methylation state. The system targets promoters, canonical CpG islands, and the more recently described \u201cshores\u201d and \u201cshelves\u201d found up to 4 kilobase pairs on either side of CpG islands. Studies have indicated that many methylation alterations are not in promoters or CpG islands, but most are within 2kb, the CpG island shore. The kit also targets known differentially methylated regions. <\/p>\n
Agilent SureSelect XT Methyl-Seq delivers higher throughput and lower costs than whole genome bisulfite sequencing. It identifies regions that are not detected by restriction enzyme-based or immunoprecipitation-based methods. Because this product is a SureSelect XT offering, Agilent provides the complete workflow solution. This includes all reagents needed for library prep and target enrichment. <\/p>\n
For more information, visit http:\/\/www.agilent.com\/genomics\/ngs<\/a>. <\/p>\n About Agilent Technologies <\/p>\n Agilent Technologies Inc. (NYSE:A - News) is the world\u2019s premier measurement company and a technology leader in chemical analysis, life sciences, electronics and communications. The company\u2019s 18,700 employees serve customers in more than 100 countries. Agilent had net revenues of $6.6 billion in fiscal 2011. Information about Agilent is available at http:\/\/www.agilent.com<\/a>. <\/p>\n NOTE TO EDITORS: Further technology, corporate citizenship and executive news is available at http:\/\/www.agilent.com\/go\/news<\/a>. <\/p>\n<\/p>\n View original post here: MARCO ISLAND, Fla.--(BUSINESS WIRE)-- (AGBT) \u2013 Agilent Technologies Inc. (NYSE:A) today expanded its target-enrichment platform with the SureSelect XT Human Methyl-Seq system for epigenetic research into DNA methylation sites Continue reading
\nTRADE NEWS: Agilent Technologies Introduces First DNA Methylation Target-Enrichment System for Disease Research<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"